Literature DB >> 12118002

Ribonuclease L proteolysis in peripheral blood mononuclear cells of chronic fatigue syndrome patients.

Edith Demettre1, Lionel Bastide, Anne D'Haese, Karen De Smet, Kenny De Meirleir, Kiet P Tiev, Patrick Englebienne, Bernard Lebleu.   

Abstract

A 37-kDa binding polypeptide accumulates in peripheral blood mononuclear cell (PBMC) extracts from chronic fatigue syndrome (CFS) patients and is being considered as a potential diagnostic marker (De Meirleir, K., Bisbal, C., Campine, I., De Becker, P., Salehzada, T., Demettre, E., and Lebleu, B. (2000) Am. J. Med. 108, 99-105). We establish here that this low molecular weight 2-5A-binding polypeptide is a truncated form of the native 2-5A-dependent ribonuclease L (RNase L), generated by an increased proteolytic activity in CFS PBMC extracts. RNase L proteolysis in CFS PBMC extracts can be mimicked in a model system in which recombinant RNase L is treated with human leukocyte elastase. RNase L proteolysis leads to the accumulation of two major fragments with molecular masses of 37 and 30 kDa. The 37-kDa fragment includes the 2-5A binding site and the N-terminal end of native RNase L. The 30-kDa fragment includes the catalytic site in the C-terminal part of RNase L. Interestingly, RNase L remains active and 2-5A-dependent when degraded into its 30- and 37-kDa fragments by proteases of CFS PBMC extract or by purified human leukocyte elastase. The 2-5A-dependent nuclease activity of the truncated RNase L could result from the association of these digestion products, as suggested in pull down experiments.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12118002     DOI: 10.1074/jbc.M201263200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

Review 1.  New insights into the role of RNase L in innate immunity.

Authors:  Arindam Chakrabarti; Babal Kant Jha; Robert H Silverman
Journal:  J Interferon Cytokine Res       Date:  2010-12-29       Impact factor: 2.607

2.  37-Kilodalton/83-kilodalton RNase L isoform ratio in peripheral blood mononuclear cells: analytical performance and relevance for chronic fatigue syndrome.

Authors:  Marc Frémont; Freya Vaeyens; C Vincent Herst; Kenny De Meirleir; Patrick Englebienne
Journal:  Clin Diagn Lab Immunol       Date:  2005-10

3.  Variability of the RNase L isoform ratio (37 kiloDaltons/83 kiloDaltons) in diagnosis of chronic fatigue syndrome.

Authors:  Kiet Phong Tiev; Mickael Briant; Mohamed Ziani; Jean Cabane; Edith Demettre; Bernard Lebleu
Journal:  Clin Diagn Lab Immunol       Date:  2005-02

Review 4.  A scientific journey through the 2-5A/RNase L system.

Authors:  Robert H Silverman
Journal:  Cytokine Growth Factor Rev       Date:  2007-07-27       Impact factor: 7.638

Review 5.  Diverse functions of RNase L and implications in pathology.

Authors:  Catherine Bisbal; Robert H Silverman
Journal:  Biochimie       Date:  2007-02-20       Impact factor: 4.079

Review 6.  The human retrovirus XMRV in prostate cancer and chronic fatigue syndrome.

Authors:  Robert H Silverman; Carvell Nguyen; Christopher J Weight; Eric A Klein
Journal:  Nat Rev Urol       Date:  2010-06-01       Impact factor: 14.432

Review 7.  Pathologic effects of RNase-L dysregulation in immunity and proliferative control.

Authors:  Heather J Ezelle; Bret A Hassel
Journal:  Front Biosci (Schol Ed)       Date:  2012-01-01

8.  Identification of a microRNA signature for the diagnosis of fibromyalgia.

Authors:  Germán Cerdá-Olmedo; Armando Vicente Mena-Durán; Vicente Monsalve; Elisa Oltra
Journal:  PLoS One       Date:  2015-03-24       Impact factor: 3.240

9.  Lack of evidence for retroviral infections formerly related to chronic fatigue in Spanish fibromyalgia patients.

Authors:  Elisa Oltra; María García-Escudero; Armando Vicente Mena-Durán; Vicente Monsalve; Germán Cerdá-Olmedo
Journal:  Virol J       Date:  2013-11-11       Impact factor: 4.099

Review 10.  Efficacy of rintatolimod in the treatment of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME).

Authors:  William M Mitchell
Journal:  Expert Rev Clin Pharmacol       Date:  2016-06       Impact factor: 5.045

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.